Live Breaking News & Updates on மருத்துவர் உலகளாவிய மதிப்பீடு
Stay updated with breaking news from மருத்துவர் உலகளாவிய மதிப்பீடு. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Kezar Presents Results of the Completed MISSION Phase 1b Study of KZR-616 at EULAR 2021 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
DUPIXENT® (dupilumab injection) now publicly reimbursed in Ontario and New Brunswick for the treatment of moderate-to-severe atopic dermatitis yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.
Rapid, substantial improvements seen with gusacitinib for chronic hand eczema Source: Sofen H, et al. Efficacy, patient reported outcomes and safety of gusacitinib (ASN002) in chronic hand eczema: Results of a phase 2b, randomized, double-blind, placebo-controlled study. Presented at: AAD VMX; April 23-25, 2021 (virtual meeting). Disclosures: Healio could not confirm relevant financial disclosures at the time of publication. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Subscribe ADDED TO EMAIL ALERTS You ve successfully added to your alerts. You will receive an email when new content is published. ....
email article More than half of patients with steroid-refractory hand eczema responded quickly to a pan-Janus kinase (JAK) inhibitor in a randomized, placebo-controlled trial. After 16 weeks of treatment, patients treated with the higher of two doses of gusacitinib had a 69.5% reduction in target lesion symptom score (TLSS), as compared with 49% among patients randomized to the lower dose of the drug, and 33.5% of placebo-treated patients. Response to gusacitinib occurred as early as 2 weeks after the start of treatment. The higher dose of the JAK inhibitor led to a 72% improvement in the Hand Eczema Severity Index (HECSI) at 16 weeks, as compared with 20.8% in the placebo arm, reported Howard Sofen, MD, of Dermatology Research Associates and the University of California Los Angeles, at the American Academy of Dermatology virtual meeting. ....
email article A majority of patients with plaque psoriasis had at least 75% improvement, and complete or near-complete clearance by physician assessment, after 16 weeks in two randomized trials of the TYK2 inhibitor deucravacitinib. The parallel POETYK PSO-1 and PSO-2 trials showed that 58.7% and 53.6% of patients treated with deucravacitinib had 75% improvement in the Psoriasis Area and Severity Index (PASI 75). Additionally, 50%-54% of patients in the two trials met the coprimary endpoint of Physician Global Assessment (PGA) score of 0/1. Both outcome values were significantly higher than those observed in placebo-treated patients and in patients randomized to apremilast (Otezla). All secondary outcomes favored deucravacitinib and achieved statistical superiority versus placebo and apremilast in most cases, reported April Armstrong, MD, of the University Southern California in Los Angeles, at the American Academy of Dermatology virtual meeting. ....